Navigation Links
Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Date:3/25/2009

CRANBURY, N.J., March 25 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the issuance on March 10, 2009 of United States Patent No. 7,501,439, titled "Tartrate Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the Company's investigational drug Plicera(TM) (afegostat tartrate), and its use for the treatment of Gaucher disease. The patent will expire in 2027.

John F. Crowley, President and CEO of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform."

Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy. This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the Company expects the results to be available in the third quarter of 2009.

Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic d
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... Calif., Dec. 5, 2011  Radient Pharmaceuticals Corporation  (OTCQX:RXPC) ... In Vitro Diagnostic (IVD) cancer test, announced ... the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were ... The meeting will be held on January 19-21, ...
... (NASDAQ and MTA: CTIC) announced today an update on ... application ("MAA") for Pixuvri. CTI is seeking a license ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") who have ... received the CHMP,s day 180 list of outstanding issues, ...
Cached Medicine Technology:Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 2European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 3European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 4European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 5
(Date:9/17/2014)... 2014 iFitDress.com, a renowned wedding dress manufacturer ... petite evening dresses . All these outfits are now offered ... shipping costs. , “iFitDress.com is a professional company when ... are now busy selling our new collection of petite evening ... order above $800 can get free shipping. All these cheap ...
(Date:9/17/2014)... York, NY (PRWEB) September 18, 2014 ... 5.9 million tons of medical waste in 2014. Due ... disposed of in landfills along with municipal solid waste. ... disposal of regulated medical waste (RMW). This includes disposable ... or other potentially infectious materials. As a result of ...
(Date:9/17/2014)... Los Angeles, CA (PRWEB) September 17, 2014 ... U.S. Food & Drug Administration report titled “Adverse ... Intranasal Splint as a Dermal Filler,” unapproved use ... filler injections has resulted in adverse reactions including ... acid based products with FDA approval for cosmetic ...
(Date:9/17/2014)... PA (PRWEB) September 17, 2014 Fitness-conscious ... exercise - even when they're already practicing or participating ... was inspired to design a special fitness system that ... playing baseball or football," said an inventor from Maynard, ... MOBILITY FITNESS SYSTEM, which maximizes a body workout while ...
(Date:9/17/2014)... has been reserved for the very healthy. Astronauts ... highest physical and psychological standards to prepare them ... of commercial spaceflight, average people can now fly ... very little information about what medical conditions or ... spaceflight environment, as most medical conditions have never ...
Breaking Medicine News(10 mins):Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Space: The final frontier… open to the public 2
... , , ATLANTA, ... related to the diagnosis and treatment of infertility with ovulation induction ... emotional, scientific and financial aspects. Discussions include information about age related ... donor sperm or donor eggs. , , ...
... , , ... officials announced today that Tennessee residents have saved over $7.3 million ... the free statewide prescription assistance program. Tennessee Drug Card, which ... 2007. The program has no restrictions to membership, no income requirements, ...
... , , MINNEAPOLIS, July 27 ... world,s population, often resulting in patches of dry skin, and little red ... the teenage years but may continue throughout adulthood. There is no ... B. Fleischer, professor and chair of the department of dermatology at Wake ...
... exercise at lower concentrations , MONDAY, July 27 (HealthDay ... have a negative effect on lung function in healthy people, ... allows for ozone concentrations of up to 75 parts per ... that 6.6 hours exposure to mean ozone concentrations as low ...
... , LA JOLLA, Calif., July 27 For the ... business leaders, community members and cancer survivors "surfing for a cure" ... held at UC San Diego,s Scripps Institution of Oceanography. Now, members ... Longboard Invitational portion of the event that takes place on Sunday, ...
... New York, NY The Lymphoma Research Foundation (LRF) is ... Research Foundation Clinical Investigator Career Development Award has been ... the Nebraska Medical Center in Omaha, Nebraska. ... is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin ...
Cached Medicine News:Health News:Tennessee Drug Card Has Saved Residents Over $7.3 Million 2Health News:What Is Keratosis Pilaris (KP)? 2Health News:'Safe' Ozone Levels May Not Be for Some 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 2Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 3Health News:Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 16 Years of 'Surfing for a Cure' to Raise Funds for Cancer Research 4Health News:Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... The HAAG-STREIT OM 900 Ophthalmometer uses ... the three requirements of Helmholtz: 1. The ... of the distance between the Ophthalmometer and ... are independent of the distance between the ...
Medicine Products: